All news

Shared voting power tops 5% in Millennium’s amended Cytek Biosciences (CTKB) stake report.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has filed an amended Schedule 13G/A report for Cytek Biosciences (CTKB), disclosing a 5.6% shared voting and dispositive power over 7,281,488 shares. Integrated Core Strategies (US) LLC also reported a 4.5% stake with 5,870,954 shares.

Read original source

CTKB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.